Duopharma Biotech Bhd - Asset Resilience Ratio
Duopharma Biotech Bhd (7148) has an Asset Resilience Ratio of 20.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Duopharma Biotech Bhd (7148) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Duopharma Biotech Bhd's Asset Resilience Ratio has changed over time. See Duopharma Biotech Bhd balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Duopharma Biotech Bhd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 7148 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RM290.87 Million | 20.08% |
| Short-term Investments | RM0.00 | 0% |
| Total Liquid Assets | RM290.87 Million | 20.08% |
Asset Resilience Insights
- Good Liquidity Position: Duopharma Biotech Bhd maintains a healthy 20.08% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Duopharma Biotech Bhd Industry Peers by Asset Resilience Ratio
Compare Duopharma Biotech Bhd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Duopharma Biotech Bhd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Duopharma Biotech Bhd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.71% | RM161.25 Million ≈ $40.48 Million |
RM1.38 Billion ≈ $345.72 Million |
-12.35pp |
| 2023-12-31 | 24.06% | RM323.59 Million ≈ $81.24 Million |
RM1.35 Billion ≈ $337.72 Million |
+17.71pp |
| 2022-12-31 | 6.34% | RM77.49 Million ≈ $19.46 Million |
RM1.22 Billion ≈ $306.78 Million |
+3.73pp |
| 2021-12-31 | 2.62% | RM30.45 Million ≈ $7.64 Million |
RM1.16 Billion ≈ $292.27 Million |
-2.37pp |
| 2020-12-31 | 4.99% | RM52.81 Million ≈ $13.26 Million |
RM1.06 Billion ≈ $265.74 Million |
+0.46pp |
| 2019-12-31 | 4.53% | RM41.67 Million ≈ $10.46 Million |
RM919.80 Million ≈ $230.93 Million |
+1.94pp |
| 2018-12-31 | 2.59% | RM21.70 Million ≈ $5.45 Million |
RM836.38 Million ≈ $209.99 Million |
-4.33pp |
| 2017-12-31 | 6.93% | RM48.86 Million ≈ $12.27 Million |
RM705.24 Million ≈ $177.06 Million |
-5.84pp |
| 2016-12-31 | 12.77% | RM84.48 Million ≈ $21.21 Million |
RM661.46 Million ≈ $166.07 Million |
-- |
About Duopharma Biotech Bhd
Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives… Read more